3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
21
Neurofibromatosis 1
19
Melanoma
11
Neurofibroma, Plexiform
10
Lung Neoplasms
8
Neoplasms
7
Neoplasm Metastasis
7
Colorectal Neoplasms
7
Breast Neoplasms
7
Solid Tumours
5
Pancreatic Neoplasms
4
Carcinoma, Hepatocellular
4
Uveal Melanoma
3
Triple Negative Breast Neoplasms
3
Thyroid Neoplasms
3
Rectal Neoplasms
3
Neurofibrosarcoma
3
Gallbladder Neoplasms
3
Colonic Neoplasms
3
Biliary Tract Neoplasms
3
Thyroid Cancer, Papillary
2
Sarcoma
2
Bile Duct Neoplasms
2
Adult Solid Neoplasm
2
Thyroid Diseases
1
Thymoma
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma, Kaposi
1
Renal Insufficiency
1
Interventions
Thyrotropin Alfa
4
donafenib
2
Injections
2
vandetanib
1
surufatinib
1
pembrolizumab
1
lenvatinib
1
apatinib
1
anlotinib
1
Sorafenib
1
Iodine-131
1
Everolimus
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Differentiated Thyroid Cancer
×
AZD 6244
×
Clear all
NCT01843062
2019-08-28
ASTRA
AstraZeneca
Phase 3
Terminated
233 enrolled
14 charts